Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 243,268,448
  • Shares Outstanding, K 6,833,384
  • Annual Sales, $ 58,120 M
  • Annual Income, $ 10,735 M
  • 60-Month Beta 0.46
  • Price/Sales 4.20
  • Price/Cash Flow 14.08
  • Price/Book 7.98
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/17/19
  • Annual Dividend & Yield 0.68 (1.91%)
  • Most Recent Dividend 0.678 on 03/07/19
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.6700 +8.30%
on 05/31/19
35.9000 -1.45%
on 06/20/19
+1.3800 (+4.06%)
since 05/24/19
3-Month
31.8050 +11.24%
on 05/13/19
35.9000 -1.45%
on 06/20/19
+1.6200 (+4.80%)
since 03/22/19
52-Week
26.9600 +31.23%
on 07/11/18
35.9000 -1.45%
on 06/20/19
+7.6100 (+27.40%)
since 06/22/18

Most Recent Stories

More News
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

AZN : 41.48 (+0.29%)
MRK : 85.51 (+1.11%)
ABBV : 78.43 (-0.44%)
RHHBY : 35.4020 (-0.56%)
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

AZN : 41.48 (+0.29%)
MRK : 85.51 (+1.11%)
JNJ : 143.06 (+0.68%)
LLY : 115.66 (+0.15%)
RHHBY : 35.4020 (-0.56%)
SNY : 43.79 (-0.82%)
BMY : 45.70 (-7.38%)
Mallinckrodt Down After Agreement with DOJ for Litigation

Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.

CELG : 93.48 (-5.49%)
MNK : 8.43 (-6.02%)
RHHBY : 35.4020 (-0.56%)
BMY : 45.70 (-7.38%)
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

AZN : 41.48 (+0.29%)
MRK : 85.51 (+1.11%)
NVS : 92.79 (+0.32%)
RHHBY : 35.4020 (-0.56%)
AMGN : 184.71 (-1.28%)
SNY : 43.79 (-0.82%)
BMY : 45.70 (-7.38%)
Blueprint Medicines to File NDA for Avapritinib With FDA

Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.

BAYRY : 15.7000 (+1.09%)
BPMC : 92.83 (-2.46%)
RHHBY : 35.4020 (-0.56%)
PFE : 43.78 (+0.25%)
Pfizer to Launch Several Drugs Despite Generic Headwinds

Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.

ABBV : 78.43 (-0.44%)
RHHBY : 35.4020 (-0.56%)
AMGN : 184.71 (-1.28%)
PFE : 43.78 (+0.25%)
Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

RHHBY : 35.4020 (-0.56%)
AMGN : 184.71 (-1.28%)
MRTX : 98.70 (-2.70%)
BMY : 45.70 (-7.38%)
Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication

Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)

MRK : 85.51 (+1.11%)
ABBV : 78.43 (-0.44%)
RHHBY : 35.4020 (-0.56%)
BMY : 45.70 (-7.38%)
Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO

Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.

BAYRY : 15.7000 (+1.09%)
MRK : 85.51 (+1.11%)
RHHBY : 35.4020 (-0.56%)
BMY : 45.70 (-7.38%)
AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer

AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.

AZN : 41.48 (+0.29%)
MRK : 85.51 (+1.11%)
RHHBY : 35.4020 (-0.56%)
BMY : 45.70 (-7.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 35.8257
1st Resistance Point 35.7128
Last Price 35.4020
1st Support Level 35.4043
2nd Support Level 35.2087

See More

52-Week High 35.9000
Last Price 35.4020
Fibonacci 61.8% 32.4849
Fibonacci 50% 31.4300
Fibonacci 38.2% 30.3751
52-Week Low 26.9600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar